+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Hepatic arterial infusion in the treatment of liver metastases with PEG liposomes in combination with degradable starch microspheres (DSM) increases tumor 5-FU concentration. an animal study in CC-531 liver tumor-bearing rats



Hepatic arterial infusion in the treatment of liver metastases with PEG liposomes in combination with degradable starch microspheres (DSM) increases tumor 5-FU concentration. an animal study in CC-531 liver tumor-bearing rats



Anticancer Research 31(1): 147-152



The regional application of cytostatics in liver metastases leads to increased concentrations in the tumor tissue. The effect of flow retardation by temporary occlusion and drug targeting with liposome encapsulation (PEG liposomes) on tumor 5-fluorouracil (5-FU) concentrations was investigated. Tumor-bearing rats were submitted to i.v. or intraarterial (i.a.) therapy with liposome-encapsulated or non-encapsulated 5-FU. The i.a. groups were additionally treated with or without Spherex® degradable starch microspheres (DSM). The tumor 5-FU concentrations were determined by high-performance liquid chromatography (HPLC) as area under the curve (AUC). A comparison with i.v. in administered 5-FU yielded the following increases tumor concentrations: 5-FU-PEG liposomes i.v. 27-fold, 5-FU i.a. 19-fold, 5-FU i.a. + DSM 1760-fold, 5-FU-PEG liposomes i.a. 110-fold, 5-FU-PEG liposomes i.a. + DSM 7665-fold. Liver intratumoral 5-FU concentration increases to >7,500 times that following i.v. administration by a combination of regional administration via the hepatic artery with temporary embolization by DSM and drug targeting by liposome-encapsulated 5-FU.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 053514028

Download citation: RISBibTeXText

PMID: 21273592


Related references

Improvement of biodistribution with PEGylated liposomes containing docetaxel with degradable starch microspheres for hepatic arterial infusion in the treatment of liver metastases: a study in CC-531 liver tumor-bearing WAG RIJ rats. Anticancer Research 31(1): 153-159, 2011

Stealth liposomal 5-fluorouracil with or without degradable starch microspheres for hepatic arterial infusion in the treatment of liver metastases. An animal study in VX-2 liver tumor-bearing rabbits. Anticancer Research 24(3a): 1699-1704, 2004

Hepatic arterial perfusion (Hai) with liposomal taxol [3h] in combination with degradable starch microspheres increases the concentration in Cc-531 liver tumor of wag rats. Gastroenterology 124(4): A386-A387, 2003

Hepatic arterial perfusion with liposomal taxol in combination with degradable starch microspheres increases the concentration in cc 531 liver tumor of wag rats. Digestive Disease Week Abstracts & Itinerary Planner : Abstract No M1631, 2003

Three cases of multiple liver metastases of carcinoid tumor responding to hepatic arterial infusion chemotherapy using degradable starch microspheres. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 29(12): 2358-2361, 2002

A case of multiple liver metastases from rectal carcinoid tumor successfully treated with arterial infusion chemotherapy using degradable starch microspheres (DSM). Nihon Shokakibyo Gakkai Zasshi 98(4): 410-415, 2001

Regional hepatic arterial infusion of degradable starch microspheres increases fluorodeoxyuridine (FUdR) tumor uptake. Surgery 105(3): 383-392, 1989

A case report of intra-hepatic arterial infusion of mitomycin C with degradable starch microspheres for liver metastases of sigmoid colon carcinoma. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 29(12): 2080-2083, 2002

Redistribution of the arterial blood flow within the liver after arterial infusion of starch degradable microspheres in patients with liver metastases from colorectal cancer. Bollettino Societa Italiana Biologia Sperimentale 61(5): 755-762, 1985

Audit of the safety of hepatic arterial infusion of degradable starch microspheres (DSM). Adriamycin (ADM).mitomycin C (MMC) on aged patients with liver metastases of colorectal cancer. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 29(12): 2374-2376, 2002

Prospective randomized controlled trial of hepatic arterial embolization or infusion chemotherapy with 5-fluorouracil and degradable starch microspheres for colorectal liver metastases. British Journal of Surgery 77(7): 779-782, 1990

Histological examination of the effect of hepatic arterial infusion of degradable starch microspheres mixed with adriamycin and mitomycin C for liver metastases of colorectal cancer--second report. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 31(11): 1800-1802, 2004

Multicenter pilot study of 5-fluorouracil, folinic acid, interferon alpha-2b and degradable starch microspheres via hepatic arterial infusion in patients with nonresectable colorectal liver metastases. Anticancer Research 24(5b): 3275-3282, 2004

Case report of a liver metastasis from rectal cancer achieving complete response (CR) by a combination of intra-hepatic arterial infusion of irinotecan (CPT-11) with degradable starch microspheres (DSM) and weekly high-dose intra-hepatic arterial chemotherapy with 5-FU. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 33(10): 1485-1488, 2006

Ischemic tumor damage using enzymatically degradable starch microspheres for prolonged arterial microembolization and metachronous regional chemotherapy for liver metastases. Langenbecks Archiv fuer Chirurgie 372: 890, 1987